HLA-A*02:01 HPV16 E7 Tetramer-YMLDLQPETT-PE

Catalog No:
MBL-TS-M048-1
$1,470.00

Formerly Catalog No.: TB-M048-1

Browse all MBL products from our MBL products homepage.

The α3 mutation significantly reduces the binding of MHC tetramer to human CD8. To minimizes the aberrant effect of some CD8 antibodies; clone SFCI21Thy2D3 (also known as “T8”) is recommended.

Product Specifications
Application FC
Reactivity Human
Conjugation PE
Peptide Sequence YMLDLQPETT
Class Class I
Sequence Location 11-20
MHC Allele A*02:01
Documents & Links for HLA-A*02:01 HPV16 E7 Tetramer-YMLDLQPETT-PE
Datasheet HLA-A*02:01 HPV16 E7 Tetramer-YMLDLQPETT-PE Datasheet

Documents & Links for HLA-A*02:01 HPV16 E7 Tetramer-YMLDLQPETT-PE
Datasheet HLA-A*02:01 HPV16 E7 Tetramer-YMLDLQPETT-PE Datasheet

Citations for HLA-A*02:01 HPV16 E7 Tetramer-YMLDLQPETT-PE – 1 Found
Quayle, Steven N; Girgis, Natasha; Thapa, Dharma R; Merazga, Zohra; Kemp, Melissa M; Histed, Alex; Zhao, Fan; Moreta, Miguel; Ruthardt, Paige; Hulot, Sandrine; Nelson, Alyssa; Kraemer, Lauren D; Beal, Dominic R; Witt, Luke; Ryabin, Jessica; Soriano, Jonathan; Haydock, Mark; Spaulding, Emily; Ross, John F; Kiener, Peter A; Almo, Steven; Chaparro, Rodolfo; Seidel, Ronald; Suri, Anish; Cemerski, Saso; Pienta, Kenneth J; Simcox, Mary Ellen. CUE-101, a Novel E7-pHLA-IL2-Fc Fusion Protein, Enhances Tumor Antigen-Specific T-Cell Activation for the Treatment of HPV16-Driven Malignancies. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research. 2020;26(8):1953-1964.  PubMed